AMGN - AMGEN Inc.
(NaN%)
Sell
Moderate Growth but Declining●Stock Price Very High
46%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 16.37%
Operating Income Growth is -34.79%
Net Income Growth is -60.77%
Earnings Per Share (EPS) Growth is -60.76%
Net Margin is 10.12%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.26
Debt Ratio is 0.26
Current Debt to Net Income Ratio is 7.41
Total Debt to Total Assets Ratio is 0.75
Cash Flow is WEAK
Cash from Operations Growth is -40.31%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
AMGEN Inc. (AMGN) - https://www.amgen.com/
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Robert Bradway
Employees - 25,200
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.